1.68m Euro seed investment for Industrial Technology and Witchcraft, a Berlin based games development company

March 30, 2022

Berlin, 30th March 2022 – Industrial Technology and Witchcraft received, in March 2022, a seed investment of 1.68m Euro in cash from investors like High-Tech Gründerfonds, a German based high-tech venture capital investor, London based DN Capital and BLN Capital, the founders of Kolibri Games.

Industrial Technology and Witchcraft is going to use the funds to develop new games with incredible mesmerizing graphics, made out of Voxels and Pixels and with epic soundtracks.

The HTGF team was the first to be convinced to invest in Mister Spex and eWings.com. Now I am happy that we will be working together for the third time.

Thilo Hardt, co-founder of Industrial Technology and Witchcraft

Thilo, as a successful HTGF serial founder, together with Tony and Ron, brings the tech, gaming and entrepreneurial expertise for a third successful startup journey. I am very excited to support Thilo and his team together with DN Capital and BLN Capital.

Frank Reinecke, principal at HTGF


About Industrial Technology and Witchcraft
Founded by Thilo Hardt and Tony Twyman, two veterans of the startup ecosystem of Berlin. Hardt co-founded Mister Spex, Europe’s leading online optician in 2007, and founded eWings.com, a business travel management software company in 2013, now part of American Express GBT. Both are software developers at heart and eager to make great games that a new generation of kids will soon recall as part of their youth.

Press contact
IT&W Games GmbH
c/o Studio Legal, Thilo Hardt
Berliner Freiheit 2
10785 Berlin
press@industrial-technology-and-witchcraft.com
https://industrial-technology-and-witchcraft.com/presskit.zip

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 4 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 150 companies.

Investors in this public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Media contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 – 82300 – 188
s.grueter@htgf.de
Investor contact
High-Tech Gründerfonds Management GmbH
Frank Kerim Reinecke, Principal
T.: +49 30 – 4036648 – 79
f.reinecke@htgf.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

Press
10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
 
Press
9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa